Replies to post #29971 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

Half, are you absurdly attempting to tell us that Stephen Frost left his position at Abbott Labs voluntarily to commute to Canada to work for an obscure company? Half, if you haven't noted, Frost is now attempting to work as a consultant back in the states.

http://biomarkerinsights.com/contact_us

I suppose Miraclins did not work out either.

[HALF FULL GLASS]

Gold,again I have not attacked any poster. Please refrain from accusations such as that.
I do not know Dr. Walsh or Dr. Gold.

What facts are you referring to? And on what do you base your assumptions that anyone abandoned Dr. Moro?

I continue to post factual information that you want to apparently ignore and you continue to post opinions as if they were factual???


"Chester (Chet) Paulson, Founder and Chairman of Paulson Investment, stated, "We believe in the Company's technology and we are pleased to be able to continue to support BioCurex. Paulson will continue to support innovative companies like BioCurex."

Preliminary studies indicate that RECAF may provide good clinical sensitivity and specificity as a tumor marker," said William Brown, Ph.D., vice president, Diagnostic Assays and Systems Development, Abbott.  "Abbott's goal is to further develop this technology, incorporating it into future tests on our ARCHITECT® system, for use in cancer diagnosis and monitoring."

BioCurex and Abbott Jointly Present RECAF Results at International Cancer Congress

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131516/


RICHMOND, British Columbia, Oct. 4, 2011 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) today announced that its article entitled: "Increased AFP-Receptor (RECAF™) Values in the Serum of Patients With Early Stages of Breast Cancer" has been accepted for publication in a peer reviewed medical journal.